These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 34654402)
1. A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII). Arakawa Y; Sasaki K; Mineharu Y; Uto M; Mizowaki T; Mizusawa J; Sekino Y; Ono T; Aoyama H; Satomi K; Ichimura K; Kinoshita M; Ohno M; Ito Y; Nishikawa R; Fukuda H; Nishimura Y; Narita Y; BMC Cancer; 2021 Oct; 21(1):1105. PubMed ID: 34654402 [TBL] [Abstract][Full Text] [Related]
2. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide. Guler OC; Yıldırım BA; Önal C; Topkan E Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447 [TBL] [Abstract][Full Text] [Related]
3. A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 (MACS study). Kadota T; Saito R; Kumabe T; Mizusawa J; Katayama H; Sumi M; Igaki H; Kinoshita M; Komori T; Ichimura K; Narita Y; Nishikawa R Jpn J Clin Oncol; 2019 Dec; 49(12):1172-1175. PubMed ID: 31804699 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Minniti G; Lanzetta G; Scaringi C; Caporello P; Salvati M; Arcella A; De Sanctis V; Giangaspero F; Enrici RM Int J Radiat Oncol Biol Phys; 2012 May; 83(1):93-9. PubMed ID: 22079725 [TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360 [TBL] [Abstract][Full Text] [Related]
7. Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. Minniti G; De Sanctis V; Muni R; Rasio D; Lanzetta G; Bozzao A; Osti MF; Salvati M; Valeriani M; Cantore GP; Maurizi Enrici R J Neurooncol; 2009 Jan; 91(1):95-100. PubMed ID: 18758912 [TBL] [Abstract][Full Text] [Related]
8. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. Minniti G; De Sanctis V; Muni R; Filippone F; Bozzao A; Valeriani M; Osti MF; De Paula U; Lanzetta G; Tombolini V; Maurizi Enrici R J Neurooncol; 2008 May; 88(1):97-103. PubMed ID: 18250965 [TBL] [Abstract][Full Text] [Related]
9. Guideline conformity to the Stupp regimen in patients with newly diagnosed glioblastoma multiforme in China. Wang Y; Zhang J; Li W; Jiang T; Qi S; Chen Z; Kang J; Huo L; Wang Y; Zhuge Q; Gao G; Wu Y; Feng H; Zhao G; Yang X; Zhao H; Wang Y; Yang H; Kang D; Su J; Li L; Jiang C; Li G; Qiu Y; Wang W; Wang H; Xu Z; Zhang L; Wang R Future Oncol; 2021 Nov; 17(33):4571-4582. PubMed ID: 34519220 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635 [TBL] [Abstract][Full Text] [Related]
11. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). Lombardi G; Pace A; Pasqualetti F; Rizzato S; Faedi M; Anghileri E; Nicolotto E; Bazzoli E; Bellu L; Villani V; Fabi A; Ferrazza P; Gurrieri L; Dall'Agata M; Eoli M; Della Puppa A; Pambuku A; D'Avella D; Berti F; Rudà R; Zagonel V J Neurooncol; 2015 Nov; 125(2):359-67. PubMed ID: 26423801 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651 [TBL] [Abstract][Full Text] [Related]
14. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme. Gainer JL; Sheehan JP; Larner JM; Jones DR J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177 [TBL] [Abstract][Full Text] [Related]
15. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182 [TBL] [Abstract][Full Text] [Related]
16. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Herrlinger U; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Sabel M; Hau P; Kortmann RD; Krex D; Grauer O; Goldbrunner R; Schnell O; Bähr O; Uhl M; Seidel C; Tabatabai G; Kowalski T; Ringel F; Schmidt-Graf F; Suchorska B; Brehmer S; Weyerbrock A; Renovanz M; Bullinger L; Galldiks N; Vajkoczy P; Misch M; Vatter H; Stuplich M; Schäfer N; Kebir S; Weller J; Schaub C; Stummer W; Tonn JC; Simon M; Keil VC; Nelles M; Urbach H; Coenen M; Wick W; Weller M; Fimmers R; Schmid M; Hattingen E; Pietsch T; Coch C; Glas M; Lancet; 2019 Feb; 393(10172):678-688. PubMed ID: 30782343 [TBL] [Abstract][Full Text] [Related]
17. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509 [TBL] [Abstract][Full Text] [Related]
18. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R; Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848 [TBL] [Abstract][Full Text] [Related]
19. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years. Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669 [TBL] [Abstract][Full Text] [Related]